An engineered factor Va prevents bleeding induced by direct-acting oral anticoagulants by different mechanisms
Open Access
- 10 August 2020
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (15), 3716-3727
- https://doi.org/10.1182/bloodadvances.2020001699
Abstract
Control of bleeding with direct-acting oral anticoagulants (DOACs) remains an unmet clinical need. Activated superFactor V (superFVa) is an engineered activated protein C (APC)–resistant FVa variant with enhanced procoagulant activity resulting from an A2/A3 domain disulfide bond and was studied here for control of DOAC-induced bleeding. SuperFVa reversed bleeding induced by FXa inhibitors (rivaroxaban, apixaban), and the FIIa inhibitor dabigatran in BalbC mice. The blocking anti-protein C and APC [(A)PC] antibody SPC-54 also reduced FXa inhibitor induced bleeding similar to superFVa, whereas dabigatran-induced bleeding was not affected. This indicated that sufficient APC was generated to contribute to bleeding in the presence of FXa inhibitors, but not in the presence of dabigatran, suggesting that mechanisms contributing to bleeding differed for FXa and FIIa inhibitors. Despite different mechanisms contributing to bleeding, superFVa effectively reduced bleeding for all DOACs, indicating the versatility of superFVa’s properties that contribute to its universal prohemostatic effects for DOAC associated bleeding. Supported by thrombin generation assays on endothelial cells in normal plasma spiked with DOACs and patient plasma anticoagulated with DOACs, 3 complementary mechanisms were identified by which superFVa achieved DOAC class-independent prohemostatic efficiency. These mechanisms are resistance to inactivation by APC, overcoming the FV activation threshold, and maximizing the efficiency of the prothrombinase complex when the available FXa is increased by FVIIa-based prohemostatics. In summary, it is this versatility of superFVa that delineates it from other prohemostatic agents as a promising class-independent rescue agent in bleeding situations associated with DOACs.This publication has 66 references indexed in Scilit:
- Clinical and mechanistic drivers of acute traumatic coagulopathyThe Journal of Trauma and Acute Care Surgery, 2013
- Antibody SPC-54 provides acute in vivo blockage of the murine protein C systemBlood Cells, Molecules, and Diseases, 2013
- Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studiesThrombosis Journal, 2013
- Apixaban versus Warfarin in Patients with Atrial FibrillationThe New England Journal of Medicine, 2011
- Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitorJournal of Thrombosis and Thrombolysis, 2011
- Rivaroxaban (BAY 59‐7939) – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxenBritish Journal of Clinical Pharmacology, 2006
- Disulfide bond‐stabilized factor VIII has prolonged factor VIIIa activity and improved potency in whole blood clotting assaysJournal of Thrombosis and Haemostasis, 2006
- Interdomain engineered disulfide bond permitting elucidation of mechanisms of inactivation of coagulation factor Va by activated protein CProtein Science, 2002
- The Endothelial Cell Protein C Receptor (EPCR) Functions as a Primary Receptor for Protein C Activation on Endothelial Cells in Arteries, Veins, and CapillariesBiochemical and Biophysical Research Communications, 1999
- COFACTOR PROTEINS IN THE ASSEMBLY AND EXPRESSION OF BLOOD CLOTTING ENZYME COMPLEXESAnnual Review of Biochemistry, 1988